# Charles River Laboratories International, Inc.: financial statements, quarterly

CRL · NYSE · CIK 1100682 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 27

Pages: [Overview](/companies/crl.md) · [Financials](/companies/crl/financials.md) · [Filings](/companies/crl/filings.md) · [Insiders](/companies/crl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/crl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-27) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,027](/filings/0001100682-24-000035.md) | [1,013 d](/filings/0001100682-26-000022.md) | [1,012](/filings/0001100682-25-000021.md) | [1,026](/filings/0001100682-25-000034.md) | [1,010](/filings/0001100682-25-000043.md) | [1,003 d](/filings/0001100682-26-000022.md) | [984](/filings/0001100682-26-000038.md) | [1,032](/filings/0001100682-26-000118.md) | [1,005](/filings/0001100682-25-000043.md) | [994 d](/filings/0001100682-26-000022.md) | [996](/filings/0001100682-26-000038.md) | [1,004](/filings/0001100682-26-000118.md) |
| Cost of revenue | $m | [665](/filings/0001100682-24-000035.md) | not reported | [667](/filings/0001100682-24-000018.md) | [672](/filings/0001100682-24-000027.md) | [661](/filings/0001100682-24-000035.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [176](/filings/0001100682-24-000035.md) | [197 d](/filings/0001100682-26-000022.md) | [186](/filings/0001100682-25-000021.md) | [170](/filings/0001100682-25-000034.md) | [199](/filings/0001100682-25-000043.md) | [196 d](/filings/0001100682-26-000022.md) | [178](/filings/0001100682-26-000038.md) | [192](/filings/0001100682-26-000118.md) | [178](/filings/0001100682-25-000043.md) | [196 d](/filings/0001100682-26-000022.md) | [159](/filings/0001100682-26-000038.md) | [229](/filings/0001100682-26-000118.md) |
| Operating income | $m | [152](/filings/0001100682-24-000035.md) | [133 d](/filings/0001100682-26-000022.md) | [126](/filings/0001100682-25-000021.md) | [152](/filings/0001100682-25-000034.md) | [117](/filings/0001100682-25-000043.md) | [(168) d](/filings/0001100682-26-000022.md) | [74.7](/filings/0001100682-26-000038.md) | [100](/filings/0001100682-26-000118.md) | [134](/filings/0001100682-25-000043.md) | [(283) d](/filings/0001100682-26-000022.md) | [120](/filings/0001100682-26-000038.md) | [120](/filings/0001100682-26-000118.md) |
| Interest expense | $m | [33.7](/filings/0001100682-23-000022.md) | [33.5 d](/filings/0001100682-24-000007.md) | [35.0](/filings/0001100682-24-000018.md) | [32.8](/filings/0001100682-25-000034.md) | [30.3](/filings/0001100682-25-000043.md) | [28.2 d](/filings/0001100682-26-000022.md) | [27.9](/filings/0001100682-26-000038.md) | [30.0](/filings/0001100682-26-000118.md) | [25.4](/filings/0001100682-25-000043.md) | [23.8 d](/filings/0001100682-26-000022.md) | [26.7](/filings/0001100682-26-000038.md) | [30.3](/filings/0001100682-26-000118.md) |
| Income tax | $m | [24.9](/filings/0001100682-24-000035.md) | [19.8 d](/filings/0001100682-26-000022.md) | [24.5](/filings/0001100682-25-000021.md) | [25.4](/filings/0001100682-25-000034.md) | [20.9](/filings/0001100682-25-000043.md) | [(3.0) d](/filings/0001100682-26-000022.md) | [10.1](/filings/0001100682-26-000038.md) | [18.7](/filings/0001100682-26-000118.md) | [31.6](/filings/0001100682-25-000043.md) | [(17.8) d](/filings/0001100682-26-000022.md) | [(15.1)](/filings/0001100682-26-000038.md) | [53.9](/filings/0001100682-26-000118.md) |
| Net income | $m | [87.4](/filings/0001100682-24-000035.md) | [187 d](/filings/0001100682-26-000022.md) | [73.0](/filings/0001100682-25-000021.md) | [94.1](/filings/0001100682-25-000034.md) | [69.7](/filings/0001100682-25-000043.md) | [(214) d](/filings/0001100682-26-000022.md) | [25.5](/filings/0001100682-26-000038.md) | [52.3](/filings/0001100682-26-000118.md) | [54.4](/filings/0001100682-25-000043.md) | [(277) d](/filings/0001100682-26-000022.md) | [(14.8)](/filings/0001100682-26-000038.md) | [(1.5)](/filings/0001100682-26-000118.md) |
| Diluted EPS | $ per share | [1.69](/filings/0001100682-24-000035.md) | not reported | [1.30](/filings/0001100682-25-000021.md) | [1.74](/filings/0001100682-25-000034.md) | [1.33](/filings/0001100682-25-000043.md) | not reported | [0.50](/filings/0001100682-26-000038.md) | [1.06](/filings/0001100682-26-000118.md) | [1.10](/filings/0001100682-25-000043.md) | not reported | [(0.30)](/filings/0001100682-26-000038.md) | [(0.03)](/filings/0001100682-26-000118.md) |
| Basic EPS | $ per share | [1.70](/filings/0001100682-24-000035.md) | not reported | [1.31](/filings/0001100682-25-000021.md) | [1.75](/filings/0001100682-25-000034.md) | [1.34](/filings/0001100682-25-000043.md) | not reported | [0.50](/filings/0001100682-26-000038.md) | [1.06](/filings/0001100682-26-000118.md) | [1.11](/filings/0001100682-25-000043.md) | not reported | [(0.30)](/filings/0001100682-26-000038.md) | [(0.03)](/filings/0001100682-26-000118.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | FY2025 (2025-12-27) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [157](/filings/0001100682-24-000035.md) | [277](/filings/0001100682-25-000011.md) | [327](/filings/0001100682-25-000021.md) | [179](/filings/0001100682-25-000034.md) | [210](/filings/0001100682-25-000043.md) | [195](/filings/0001100682-26-000022.md) | [229](/filings/0001100682-26-000038.md) | [183](/filings/0001100682-26-000118.md) | [207](/filings/0001100682-25-000043.md) | [214](/filings/0001100682-26-000118.md) | [192](/filings/0001100682-26-000038.md) | [192](/filings/0001100682-26-000118.md) |
| Current assets | $m | [1,444](/filings/0001100682-23-000022.md) | [1,609](/filings/0001100682-25-000011.md) | [1,668](/filings/0001100682-24-000018.md) | [1,499](/filings/0001100682-24-000027.md) | [1,495](/filings/0001100682-24-000035.md) | [1,403](/filings/0001100682-26-000022.md) | [1,506](/filings/0001100682-25-000021.md) | [1,470](/filings/0001100682-25-000034.md) | [1,532](/filings/0001100682-25-000043.md) | [1,447](/filings/0001100682-26-000118.md) | [1,489](/filings/0001100682-26-000038.md) | [1,529](/filings/0001100682-26-000118.md) |
| Total assets | $m | [7,607](/filings/0001100682-23-000022.md) | [8,195](/filings/0001100682-25-000011.md) | [8,153](/filings/0001100682-24-000018.md) | [7,948](/filings/0001100682-24-000027.md) | [8,004](/filings/0001100682-24-000035.md) | [7,528](/filings/0001100682-26-000022.md) | [7,582](/filings/0001100682-25-000021.md) | [7,561](/filings/0001100682-25-000034.md) | [7,514](/filings/0001100682-25-000043.md) | [7,135](/filings/0001100682-26-000118.md) | [7,730](/filings/0001100682-26-000038.md) | [7,532](/filings/0001100682-26-000118.md) |
| Current liabilities | $m | [994](/filings/0001100682-23-000022.md) | [1,055](/filings/0001100682-25-000011.md) | [955](/filings/0001100682-24-000018.md) | [948](/filings/0001100682-24-000027.md) | [1,012](/filings/0001100682-24-000035.md) | [994](/filings/0001100682-26-000022.md) | [1,051](/filings/0001100682-25-000021.md) | [1,080](/filings/0001100682-25-000034.md) | [1,122](/filings/0001100682-25-000043.md) | [1,120](/filings/0001100682-26-000118.md) | [1,094](/filings/0001100682-26-000038.md) | [1,135](/filings/0001100682-26-000118.md) |
| Total liabilities | $m | [4,256](/filings/0001100682-23-000022.md) | [4,536](/filings/0001100682-25-000011.md) | [4,449](/filings/0001100682-24-000018.md) | [4,175](/filings/0001100682-24-000027.md) | [4,176](/filings/0001100682-24-000035.md) | [4,020](/filings/0001100682-26-000022.md) | [4,341](/filings/0001100682-25-000021.md) | [4,161](/filings/0001100682-25-000034.md) | [4,063](/filings/0001100682-25-000043.md) | [3,924](/filings/0001100682-26-000118.md) | [4,742](/filings/0001100682-26-000038.md) | [4,644](/filings/0001100682-26-000118.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [0.8](/filings/0001100682-23-000022.md) | [3.2](/filings/0001100682-25-000011.md) | [0.5](/filings/0001100682-24-000018.md) | [0.4](/filings/0001100682-24-000027.md) | [0.2](/filings/0001100682-24-000035.md) | [0.2](/filings/0001100682-26-000022.md) | [0.1](/filings/0001100682-25-000021.md) | [0.1](/filings/0001100682-25-000034.md) | [0.1](/filings/0001100682-25-000043.md) | [0.2](/filings/0001100682-26-000118.md) | [6.7](/filings/0001100682-26-000038.md) | [5.5](/filings/0001100682-26-000118.md) |
| Shareholders' equity | $m | [3,306](/filings/0001100682-23-000022.md) | [3,597](/filings/0001100682-25-000011.md) | [3,640](/filings/0001100682-24-000018.md) | [3,723](/filings/0001100682-24-000027.md) | [3,782](/filings/0001100682-24-000035.md) | [3,462](/filings/0001100682-26-000022.md) | [3,194](/filings/0001100682-25-000021.md) | [3,353](/filings/0001100682-25-000034.md) | [3,405](/filings/0001100682-25-000043.md) | [3,165](/filings/0001100682-26-000118.md) | [2,941](/filings/0001100682-26-000038.md) | [2,840](/filings/0001100682-26-000118.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-27) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [205 d](/filings/0001100682-24-000035.md) | [221 d](/filings/0001100682-26-000022.md) | [130](/filings/0001100682-25-000021.md) | [194 d](/filings/0001100682-25-000034.md) | [252 d](/filings/0001100682-25-000043.md) | [159 d](/filings/0001100682-26-000022.md) | [172](/filings/0001100682-26-000038.md) | [205 d](/filings/0001100682-26-000118.md) | [214 d](/filings/0001100682-25-000043.md) | [148 d](/filings/0001100682-26-000022.md) | [41.1](/filings/0001100682-26-000038.md) | [180 d](/filings/0001100682-26-000118.md) |
| Capital expenditure | $m | [65.9](/filings/0001100682-24-000035.md) | [78.3 d](/filings/0001100682-26-000022.md) | [79.1](/filings/0001100682-25-000021.md) | [39.5](/filings/0001100682-25-000034.md) | [38.7](/filings/0001100682-25-000043.md) | [75.6 d](/filings/0001100682-26-000022.md) | [59.3](/filings/0001100682-26-000038.md) | [35.3](/filings/0001100682-25-000034.md) | [35.6](/filings/0001100682-25-000043.md) | [89.0 d](/filings/0001100682-26-000022.md) | [55.9](/filings/0001100682-26-000038.md) | [31.1 d](/filings/0001100682-26-000118.md) |
| Share repurchases | $m | [0.0 d](/filings/0001100682-24-000035.md) | [0.1 d](/filings/0001100682-26-000022.md) | [9.4](/filings/0001100682-25-000021.md) | [8.9 d](/filings/0001100682-25-000034.md) | [101 d](/filings/0001100682-25-000043.md) | [0.1 d](/filings/0001100682-26-000022.md) | [353](/filings/0001100682-26-000038.md) | [7.4 d](/filings/0001100682-26-000118.md) | [0.1 d](/filings/0001100682-25-000043.md) | [0.1 d](/filings/0001100682-26-000022.md) | [208](/filings/0001100682-26-000038.md) | [116 d](/filings/0001100682-26-000118.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-24) | Q1 FY2023 (2023-04-01) | Q2 FY2023 (2023-07-01) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [51.3](/filings/0001100682-23-000022.md) | [51.4](/filings/0001100682-24-000018.md) | [51.5](/filings/0001100682-24-000027.md) | [51.6](/filings/0001100682-24-000035.md) | [51.8](/filings/0001100682-25-000021.md) | [51.8](/filings/0001100682-25-000034.md) | [51.6](/filings/0001100682-25-000043.md) | [50.9](/filings/0001100682-26-000038.md) | [49.3](/filings/0001100682-26-000118.md) | [49.4](/filings/0001100682-25-000043.md) | [49.0](/filings/0001100682-26-000038.md) | [48.0](/filings/0001100682-26-000118.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 47,738,872 at 2026-07-25, from the cover of the [10-Q filed 2026-08-05](/filings/0001100682-26-000118.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.